BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Posted by Francis Steltz on Aug 1st, 2026

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve analysts that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $20.80.

BCRX has been the topic of several research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a research note on Monday, July 13th. They issued a “neutral” rating and a $12.00 price objective for the company. Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Wedbush cut their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th.

Check Out Our Latest Stock Report on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Stock Down 2.8%

NASDAQ:BCRX opened at $8.98 on Monday. The company has a fifty day moving average of $9.30 and a 200-day moving average of $8.63. The firm has a market capitalization of $2.28 billion, a P/E ratio of -5.04 and a beta of 0.55. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm’s revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 earnings per share. On average, analysts anticipate that BioCryst Pharmaceuticals will post -2.58 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of BCRX. RA Capital Management L.P. bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at $123,452,000. Deerfield Management Company L.P. increased its position in BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares during the last quarter. Janus Henderson Group PLC increased its position in BioCryst Pharmaceuticals by 7,807.2% in the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after buying an additional 7,310,745 shares during the last quarter. Perceptive Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 135.1% in the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after buying an additional 4,271,504 shares during the period. Finally, Bank of America Corp DE raised its stake in shares of BioCryst Pharmaceuticals by 231.6% in the first quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock valued at $48,474,000 after buying an additional 3,556,208 shares during the period. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.